Denali Therapeutics (DNLI)
(Real Time Quote from BATS)
$30.16 USD
-0.16 (-0.53%)
Updated Sep 25, 2024 10:16 AM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Brokerage Reports
0 items in cart
Denali Therapeutics Inc. [DNLI]
Reports for Purchase
Showing records 1 - 20 ( 204 total )
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Turns Out "When Not If" Was Right; Tividenofusp Accelerated Approval Path Opens
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
OTV Platform Transformational for ASO Based Therapeutic Strategy for Neurodegenerative Diseases
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
ATV:Anti-Abeta Program Holds Promise as the Next-Generation AD Drug; PT Down to $90
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Implications for the Abeta Therapeutic Landscape Following Kisunla Approval
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Donanemab Nears Approval - Implications for the Next Generation AD Therapies
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A